Plasma phosphorylated tau217 strongly associates with memory deficits in the Alzheimer’s disease spectrum - Scorecard - MDSpire

Plasma phosphorylated tau217 strongly associates with memory deficits in the Alzheimer’s disease spectrum

  • By

  • Jaime Fernández Arias

  • Wagner S Brum

  • Gemma Salvadó

  • Joseph Therriault

  • Stijn Servaes

  • Yi-Ting Wang

  • Etienne Aumont

  • Nesrine Rahmouni

  • Arthur C Macedo

  • Kely Monica Quispialaya

  • Seyyed Ali Hosseini

  • Peter Kunach

  • Wan Lu Jia

  • Tevy Chan

  • Lydia Trudel

  • Brandon Hall

  • Yanseng Zheng

  • Sejal Mohapatra

  • Sulantha S Mathotaarachchi

  • Paolo Vitali

  • Cécile Tissot

  • Gleb Bezgin

  • Yasser Iturria-Medina

  • Nicholas J Ashton

  • Andréa Lessa Benedet

  • Thomas K Karikari

  • Gallen Triana-Baltzer

  • Jesse M Klostranec

  • Hartmuth C Kolb

  • Eduardo R Zimmer

  • Shorena Janelidze

  • Niklas Mattsson-Carlgren

  • Erik Stomrud

  • Sebastian Palmqvist

  • Henrik Zetterberg

  • Kaj Blennow

  • Tharick Pascoal

  • Maxime Montembeault

  • Oskar Hansson

  • Pedro Rosa-Neto

  • January 29, 2025

  • 0 min

Share

Clinical Scorecard: Elevated Plasma Phosphorylated Tau217 Correlates with Cognitive Impairments in the Spectrum of Alzheimer’s Disease

At a Glance

CategoryDetail
ConditionAlzheimer’s disease
Key MechanismsAccumulation of amyloid-β plaques and hyperphosphorylated tau leading to neurofibrillary tangles and cognitive decline
Target PopulationCognitively unimpaired elderly and cognitively impaired, amyloid-β-positive older adults
Care SettingNeurology and memory clinics, research cohorts

Key Highlights

  • Plasma p-tau217 shows stronger association with cognitive performance, especially memory, than p-tau181 and p-tau231.
  • Plasma p-tau217 outperforms other plasma p-tau biomarkers in identifying memory and executive function impairments.
  • Memory deficits are detectable in amyloid-β- and plasma p-tau-positive individuals without significant neocortical tau PET positivity.

Guideline-Based Recommendations

Diagnosis

  • Use plasma p-tau217 as a minimally invasive biomarker to identify early cognitive impairment related to Alzheimer’s disease.
  • Incorporate ATN framework with separate consideration of fluid p-tau (T1) and tau PET (T2) biomarkers for staging.

Management

  • Monitor plasma p-tau217 levels to assess progression of memory impairment in Alzheimer’s disease spectrum.

Monitoring & Follow-up

  • Regular cognitive assessments focusing on memory and executive function domains in amyloid-β- and plasma p-tau-positive individuals.
  • Use plasma p-tau217 to track neuronal network disturbance and cognitive decline.

Risks

  • Potential underestimation of cognitive impairment if relying solely on tau PET without plasma p-tau biomarkers.

Patient & Prescribing Data

Elderly individuals with or without cognitive impairment and amyloid-β positivity

Plasma p-tau217 can serve as a sensitive biomarker to identify early cognitive deficits, guiding timely intervention strategies.

Clinical Best Practices

  • Employ plasma p-tau217 measurement alongside amyloid biomarkers for early detection of Alzheimer’s-related cognitive impairment.
  • Apply the updated ATN framework distinguishing fluid p-tau and tau PET biomarkers for comprehensive staging.
  • Focus cognitive testing on memory domains when plasma p-tau217 is elevated, even in absence of tau PET positivity.

References

Original Source(s)

Plasma phosphorylated tau217 strongly associates with memory deficits in the Alzheimer’s disease spectrum

  • by Jaime Fernández Arias, Wagner S Brum, Gemma Salvadó, Joseph Therriault, Stijn Servaes, Yi-Ting Wang, Etienne Aumont, Nesrine Rahmouni, Arthur C Macedo, Kely Monica Quispialaya, Seyyed Ali Hosseini, Peter Kunach, Wan Lu Jia, Tevy Chan, Lydia Trudel, Brandon Hall, Yanseng Zheng, Sejal Mohapatra, Sulantha S Mathotaarachchi, Paolo Vitali, Cécile Tissot, Gleb Bezgin, Yasser Iturria-Medina, Nicholas J Ashton, Andréa Lessa Benedet, Thomas K Karikari, Gallen Triana-Baltzer, Jesse M Klostranec, Hartmuth C Kolb, Eduardo R Zimmer, Shorena Janelidze, Niklas Mattsson-Carlgren, Erik Stomrud, Sebastian Palmqvist, Henrik Zetterberg, Kaj Blennow, Tharick Pascoal, Maxime Montembeault, Oskar Hansson, Pedro Rosa-Neto

  • January 29, 2025

Related Content

ARPA-H Launches New Program to Deliver Rigorous, Gold-Standard Research Faster

Association between neurodegenerative plasma biomarkers and geriatric depression in older adults with and without clinical dementia in Kinshasa, Democratic Republic of the Congo

The effects of transcranial direct current stimulation on global cognitive function, visuospatial function, and executive function in patients with mild cognitive impairment and Alzheimer’s disease: a meta-analysis